Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis

被引：0
|
作者：
Mukhtar, Humza [1 ]
Yasmeen, Uzma [2 ]
Siddiqa, Sania [3 ]
Sarfraz, Zouina [4 ]
Sarfraz, Azza [5 ]
机构：
[1] Independent Med Coll, Faisalabad, Pakistan
[2] Faisalabad Med Univ, Faisalabad, Pakistan
[3] Ameer Ud Din Med Coll, Lahore, Pakistan
[4] Fatima Jinnah Med Univ, Lahore 54000, Punjab, Pakistan
[5] Aga Khan Univ, Karachi, Pakistan
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2022年 / 65卷
关键词：
Ublituximab; Teriflunomide; Multiple sclerosis; Relapsing; Clinical trial;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS). With limited therapeutics available, this original meta-analysis seeks to determine the effect size (using RevMan 5.4.1) for annualized relapse rate (ARR), MRI outcomes and no evidence of disease activity (NEDA) by two years post-initiation of Ublituximab. Two RCTs (N = 1094) reveal Cohen's d for ARR= -0.17 (P = 0.006) favoring Ublituximab. MRI-tested, week 96 findings of T1 (Cohen's d= -0.43, P < 0.00001) and T2 (Cohen's d= -0.55; P < 0.00001) lesions favor Ublituximab compared to Teriflunomide. Less disease activity was reported in the Ublituximab group (OR=3.33, P < 0.00001). Further trials are required to corroborate findings.
引用
收藏
页数：10
相关论文
共 50 条
  • [31] Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis
    Prakash, R. S.
    Snook, E. M.
    Lewis, J. M.
    Motl, R. W.
    Kramer, A. F.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (09) : 1250 - 1261
  • [32] Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis
    Garnock-Jones, Karly P.
    CNS DRUGS, 2013, 27 (12) : 1103 - 1123
  • [33] The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis
    Yang, Ting
    Tian, Xin
    Chen, Chao-Yang
    Ma, Ling-Yun
    Zhou, Shuang
    Li, Min
    Wu, Ye
    Zhou, Ying
    Cui, Yi-Min
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (04) : 637 - 645
  • [34] Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Terzi, Murat
    Ozer, Bilge
    Turkoglu, Recai
    Karabudak, Rana
    Efendi, Husnu
    Soysal, Aysun
    Sevim, Serhan
    Altintas, Ayse
    Kurne, Asli
    Akcali, Aylin
    Akman, Gulsen
    Yuceyar, Nur
    Balci, Belgin Petek
    Ekmekci, Ozgul
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Altunrende, Burcu
    Turan, Omer Faruk
    GozubatikCelik, Gokcen
    Kale, Nilufer
    Koseoglu, Mesrure
    Ozakbas, Serkan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36
  • [35] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Muller, Jannis
    Schadelin, Sabine
    Lorscheider, Johannes
    Benkert, Pascal
    Hanni, Peter
    Schmid, Jurg
    Kuhle, Jens
    Derfuss, Tobias
    Granziera, Cristina
    Yaldizli, Ozgur
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (12) : 3809 - 3818
  • [36] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Mueller, J.
    Schaedelin, S.
    Benkert, P.
    Haenni, P.
    Schmid, J.
    Derfuss, T.
    Kuhle, J.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 676 - 676
  • [37] Disability changes in the absence of relapse in the phase 3 ULTIMATE I and II studies of ublituximab versus teriflunomide in participants with relapsing multiple sclerosis
    Wray, S.
    Steinman, L.
    Hartung, H. -P.
    Fox, E. J.
    Alvarez, E.
    Qian, P.
    Robertson, D.
    Huang, D.
    Selmaj, K.
    Wynn, D.
    Bosco, J. A.
    Garner, C. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 333 - 334
  • [38] Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis
    Zagmutt, Francisco J.
    Carroll, Cathryn A.
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2015, 125 (11) : 798 - 807
  • [39] Teriflunomide levels in women whose male sexual partner is on teriflunomide for relapsing multiple sclerosis
    Guarnaccia, Joseph B.
    Cabot, Ann
    Garten, Lore L.
    Napoli, Salvatore
    Hasbani, Mayer J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [40] Results of the Phase 3 OPTIMUM Study of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis
    Jones, R.
    Turkoz, I.
    Ait-Tihyaty, M.
    DiBernardo, A.
    Houtchens, M.
    Havrdova, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 59 - 60
12345